ANMerge

ANMerge is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company's lead program, ANM-101, is a small molecule modulator of the Sigma-1 receptor, which plays a critical role in maintaining neuronal health and proteostasis. ANMerge's approach emphasizes neuroprotection and the restoration of cellular function to address the underlying pathology of cognitive decline. Based in Redwood City, California, the company is currently progressing its lead candidate through Phase 1 clinical testing. The founding team brings significant expertise in cognitive assessment and neurobiology to the development of disease-modifying therapies.